- Home
- LODE vs GNLX Comparison
LODE vs GNLX Comparison
Compare LODE & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LODE | GNLX |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 202.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | LODE | GNLX |
|---|---|---|
| Price | $3.27 | $4.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.00 | ★ $19.75 |
| AVG Volume (30 Days) | ★ 831.1K | 187.8K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,778,445.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,798.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.99 | N/A |
| 52 Week Low | $1.67 | $1.99 |
| 52 Week High | $10.10 | $8.54 |
Technical Indicators
Market Signals| Indicator | LODE | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 33.23 |
| Support Level | $3.13 | $4.37 |
| Resistance Level | $3.75 | $4.75 |
| Average True Range (ATR) | 0.24 | 0.41 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 25.00 | 0.82 |
Price Performance
Historical ComparisonAbout LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.